News & Press Releases
Filter by:
Mintz and ML Strategies Represent GE in Acquisition and Permitting of GE Innovation Point
January 27, 2017
Mintz attorneys represented GE in the acquisition and permitting of GE Innovation Point, GE’s new corporate headquarters. The acquisition marks a major milestone for GE, which in January 2016 announced its decision to move to Boston.
Mintz Expands National IP Litigation Capabilities with Addition of Top Silicon Valley Attorney
January 17, 2017
Mintz has bolstered its nationally recognized, bicoastal Intellectual Property Practice with the addition of veteran Silicon Valley attorney Stephen J. Akerley, who will serve as a Member in the San Francisco office.
Mintz attorneys represented venture capital firm General Catalyst in a $33 million Series B investment in Lemonade, Inc., an insurance startup. General Catalyst led the funding along with GV, Thrive Capital, Tusk Ventures, Aleph, Sequoia, and XL Innovate.
Mintz Receives its Tenth Consecutive Perfect Score on Human Rights Campaign Foundation’s 2017 Corporate Equality Index
December 12, 2016
For the tenth straight year, Mintz has received a top rating of 100% on the Corporate Equality Index, a national benchmarking survey and report on corporate policies and practices related to LGBT workplace equality, administered by the Human Rights Campaign Foundation.
Mintz Attorneys Eddie Wang Rodriguez and Jeremy D. Glaser Named to San Diego Business Journal’s List of 500 Influential Business Leaders
December 08, 2016
Eddie Wang Rodriguez, Managing Member of Mintz's San Diego office, and Jeremy D. Glaser, Co-chair of the Venture Capital & Emerging Companies Practice, have been named to the San Diego Business Journal’s San Diego 500: The Book of Influential Business Leaders.
Mintz Completes $24.5 Million Financing on Behalf of Neurotrope, Inc.
December 07, 2016
Mintz attorneys completed a $24.5 million financing in a private placement of common stock and warrants exercisable for common stock on behalf of Neutotrope, Inc., a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease.
Press Contact